A Controlled Human Pneumococcal Infection Model (PIM) Study (PIM)

  • End date
    May 17, 2023
  • participants needed
  • sponsor
    Radboud University Medical Center
Updated on 17 June 2022
Accepts healthy volunteers


Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly. Although pneumococcal vaccines exist, they do not provide complete protection and new strategies to combat this pathogen are urgently needed. Asymptomatic infection of S. pneumoniae in the human nasopharynx precedes the development of pneumococcal disease. Previously, an Experimental Human Pneumococcal Carriage (EHPC) model has been developed at the Liverpool School of Tropical Medicine (LSTM). The current study entails to establish this model in healthy adults living in the Netherlands using the inoculation dose currently used at LSTM.

Healthy adult participants (M/F) will be inoculated intranasally with strain BHN418, a penicillin sensitive serotype 6B strain of S. pneumoniae that was previously isolated from a healthy carrier. Following inoculation, participants will be monitored and blood and nasal samples will be collected over a period of 28 ± 3 days. Participants will receive a course of amoxicillin to eradicate infection on or shortly after the last visit at day 28 ± 3, unless S. pneumoniae is not detected on both day 14 and 28 ± 3 post-inoculation.

Condition Streptococcus Pneumoniae Infection
Treatment Amoxicillin 500 Mg, Sp_6B, Pheneticillin 250 mg
Clinical Study IdentifierNCT05361499
SponsorRadboud University Medical Center
Last Modified on17 June 2022


Yes No Not Sure

Inclusion Criteria

Participant is aged ≥ 18 and < 50 years on the day of the baseline visit
Participant is in good health as confirmed by review of medical history and physical examination
Participant has adequate understanding of the procedures of the study and agrees to abide strictly thereby
Participant has a home address within the Netherlands
Participant is fully conversant in the Dutch language
Participant is able to communicate easily by both mobile telephone and text messaging
Participant is available to attend all study visits
Participant agrees to inform his/her general practitioner (GP), in case applicable, about participation in the study and signs a request to release any relevant medical information concerning possible contra-indications for participation in the study by the GP
Participant agrees to provide access to information regarding the vaccination background
Participant agrees to provide a treating physician access to all study-related information and data in case an adverse event occurs
Participant is able to arrive within 3h at the Radboudumc at any time during the study participation and participant is able to arrive within 1h at the Radboudumc from his/her home address. The participant must have a home address and live in the Netherlands
Participant is willing to take an antibiotic regiment after inoculation with S. pneumoniae according to the study protocol
Participant has signed informed consent
Participant is able to answer all questions of the pre-consent questionnaire correctly

Exclusion Criteria

Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results
Smoking: Any smoking event in the last month, including (e-)cigarette, joint, cigar and pipe
Previous pneumococcal vaccination or infection with the pneumococcus at screening or inclusion visit
Close physical contact with at risk individuals, i.e. children under 5 years of age, immunosuppressed adults, frail elderly, chronically ill individuals. Close physical contact is defined as
living in the same household
having work-related contact
spending more than 1 hour/day together with an at risk individual at less than 1.5 meter distance
Illness at screening visit, illness at baseline (including mild upper respiratory
tract infection, common cold, running nose), acute illness within 3 days prior
to inoculation
Any antibiotic treatment within 2 weeks before inoculation
For female participants: pregnancy, lactation or intention to become pregnant during the study. Female volunteers are required to use an effective form of contraception during this study
Known hypersensitivity to or contra-indications (including co-medication) for use of penicillin
Receipt of any vaccinations in the two weeks prior to the start of the study (inoculation) or plans to receive any other vaccinations during the study period
Participation in any other clinical study (unless observational) in the three months prior to the start of the study or during the study period
Being an employee or student of the department of Laboratory Medicine, Radboudumc
Any other condition or situation that would, in the opinion of the investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note